# Mechanically pulverise one tumour with ultrasound to wake the immune system

Source: https://onco.cc/ideas/idea-bio2-histotripsy-immune-priming/  
OnCo record `idea-bio2-histotripsy-immune-priming` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Focused ultrasound can break a tumour apart without heat or cuts, leaving debris the immune system can learn from. Doing that to one tumour may help treat the rest.

## Summary

Histotripsy destroys tissue mechanically through cavitation, is now approved for liver tumour destruction, and leaves antigenic debris and intact immune signals rather than the coagulated protein produced by thermal ablation. Mouse studies show abscopal effects and increased T-cell priming, and combination with checkpoint blockade is being explored in early trials.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Histotripsy of a single index lesion plus checkpoint blockade produces higher rates of response in non-treated lesions than checkpoint blockade alone, with increased tumour-specific T-cell clones in blood.
- Rationale: Unlike thermal ablation or radiotherapy, mechanical disruption preserves antigen structure and releases intact damage signals, giving a mechanistic reason to expect stronger priming. The device is already approved for liver lesions, so access is straightforward.
- Proposed test: A randomised phase 2 in liver-metastatic disease comparing checkpoint blockade with or without histotripsy of one lesion, with response in untreated lesions and blood T-cell receptor expansion as endpoints.
- Maturity: early-clinical
- Actor: clinic

## Sources

- Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019): https://doi.org/10.1001/jamanetworkopen.2019.2535

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- technologies: [Focused ultrasound & histotripsy](https://onco.cc/technologies/hifu-histotripsy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Irreversible electroporation (NanoKnife)](https://onco.cc/technologies/irreversible-electroporation/), [Thermal ablation (RFA, microwave, cryo)](https://onco.cc/technologies/thermal-ablation/)
- companies: [HistoSonics](https://onco.cc/companies/histosonics/)
- terms: [Abscopal effect](https://onco.cc/terms/abscopal-effect/), [Immunogenic cell death](https://onco.cc/terms/immunogenic-cell-death/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/), [Surgery and radiotherapy cure most, get least](https://onco.cc/bottlenecks/b-surgery-radiation-innovation/)
- key papers: [Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs](https://onco.cc/key-papers/paper-haslam-jama-netw-open/)

---
JSON: https://onco.cc/api/v1/entities/idea-bio2-histotripsy-immune-priming.json